260 Stock Overview
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$6.40 |
| 52 Week Low | US$3.00 |
| Beta | 1.27 |
| 1 Month Change | 0% |
| 3 Month Change | -0.89% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 260 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -1.0% |
| 1Y | n/a | -22.2% | 2.2% |
Return vs Industry: Insufficient data to determine how 260 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 260 performed against the German Market.
Price Volatility
| 260 volatility | |
|---|---|
| 260 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 260 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 260's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 64 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861.
Centessa Pharmaceuticals plc Fundamentals Summary
| 260 fundamental statistics | |
|---|---|
| Market cap | €558.51m |
| Earnings (TTM) | -€163.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs 260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 260 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$172.65m |
| Earnings | -US$172.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 26.5% |
How did 260 perform over the long term?
See historical performance and comparison